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MEHRAN models provide two risk scores that predict the likelihood of major
bleeding in patients hospitalized with ACS.
The aim of this studY: was to evaluate the performance of CRUSADE
AND MEHRAN risk scores to predict in-hospital major bleeding in a contem-
porary cohort of patients hospitalized for ACS in Tunisia.
Methods and results: The study subjects were 205 consecutive patients
admitted to our center between January 2010 and June 2010 with ACS. For
each patient, we calculated both the CRUSADE AND MEHRAN risk score
and evaluated its discrimination by the C statistic. 
By CRUSADE and MEHRAN risk scores, our patients were classified as high
or very high risk of major bleeding in 46.3%, 32.2% of cases, respectively.
The overall incidence of in-hospital bleeding events and major bleeding
(TIMI major definition) was 19.5%, 3.9%, respectively. The major bleeding
rate increased with the CRUSADE risk category: very low, 0%; low, 0%;
moderate, 3.8%; high, 4.0%; and very high, 13.3% (P=0.004). A stepwise
increase in rates of major bleeding with increasing MEHRAN score was also
noted (0%, 0%, 4.2% vs 9.9%; p=0.01). CRUSADE and MEHRAN risk
scores demonstrated a high performance for predicting in-hospital major
bleeding (c-statistic=0.86 and 0.83, respectively).
Conclusions: In routine clinical practice, bleeding is a relatively frequent
non-cardiac complication of contemporary therapy for ACS. These two scores
discriminate major bleeding risk and are both potentially useful in clinical
decision-making during ACS.
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Background: Dealing with thrombotic risk of stent occlusion and hemor-
rhagic risk of surgery is not well documented in literature. Endothelial progen-
itor cells (EPCs), have been demonstrated to achieve a complete and
functional reendothelialization of expended coronary stent in 48 hours in
animal model. EPCs are captured by antibodies and immobilized on the stent
surface of the Genous stent (Orbus Medical). 
Method: 11 patients, 7 male, 4 female, 77.4+/–7.37 year old, presented an
acute coronary syndrome with severe coronary artery lesions and an urgent
surgical indication underwent PTCA with exclusive one or more Genous stent
(Orbus Medical). Single unique bolus of 10 mg/kg of clopidogrel associated
to 2 mg/kg of aspirin was given at least 6 hours prior PTCA. Surgery was
planned to be performed at day 5 following half pool platelet renewal. Inform
consent was obtained for all patients. 
Results: 1.72+/–0.78 stent was implanted for a total length of 28+/–12 mm
and a mean diameter of 3.0+/–0.5 mm. All target selected lesions included
left main (n=1), LAD (n=9), CX (n=3), RCA (n=6) were treated with angi-
ographic success. Mean ventricular ejection fraction was 55.0+/–0.5. Sur-
gery was performed in average at day 5 under aspirin alone (2 mg/kg) with
success of the planed surgical act (colectomy, prostatectomy, cholester-
olemy, mammectomy, gastrectomy, peripheral arterial graft) with no com-
plication. Intra venous nitrate was used for patients presenting incomplete
revascularization and distal lesions. Only one patient needed a blood trans-
fusion. At one month no event was observed (death, myocardial infarction,
repeat PTCA, cerebral event, stent thrombosis). 
Conclusion: Single bolus of clopidogrel for high risk evolutive coronary
artery lesions treated with Genous stent allow a surgical act at day 5 under
aspirin alone in good condition with no complication in this short series.
Those preliminary data can serve as an impetus for multi-center studies.
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Background: Clopidogrel and statins are frequently administered in
patients with ischemic heart disease or other atherothrombotic manifestations
and are effective in the prevention of cardiovascular disease. Clopidogrel is a
pro-drug metabolised in the liver to the active compound which inhibits the
P2Y (12) ADP platelet receptor. The aim of this study was to assess the asso-
ciation between the loss-of-function cytochrome P450 2C19 (CYP2C19)*2
variant, the use of statins which are metabolized by the CYP3A4 system and
ischemic outcomes (major adverse cardiovascular events [MACE]) in patients
treated with clopidogrel.
Methods: Between May 2009, and september 2010, 100 patients who
underwent a percutaneous coronary intervention (PCI) and were exposed to
clopidogrel treatment for at least one month, were enrolled in our study. They
underwent CYP2C19*2 determination. The primary endpoint was a composite
of death, myocardial infarction, and urgent coronary revascularisation occur-
ring during exposure to clopidogrel.
Results: 94% of our patients were on statins. Among these patients, 57%
were on statins metabolized by CYP3A4 (simvastatin or atorvastatin) and 37%
in statin not metabolized by CYP 3A4 (Rosuvastatin, Fluvastatin and Pravas-
tatin). Statins metabolized by CYP3A4 have no effect on the occurrence of
MACE under clopidogrel (p=0, 18). In the group of patients on statins metab-
olized by CYP3A4, no statistically significant difference was observed
regarding the occurrence of intra hospital MACE according to genetic profile
(11, 1% in the non mutated group versus 25 % in the mutated group).
Conclusion: The results of our study are consistent with those of the liter-
ature and have not shown any association between major cardiovascular
events and the use of statins metabolized by CYP3A4, this genotype.
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Background: Acute myocardial infarction (AMI) is the clinical manifesta-
tion of the chronic development of coronary artery atheroma, with the final
process of plaque rupture and coronary thrombosis. Plasma lipoprotein (a)
(Lp(a)) levels are mainly genetically determined. The C93T and G121A poly-
morphisms are a naturally occurring variant of the LPA gene that may influ-
ence Lp(a) concentration. The role of Lp(a) in the pathogenesis of myocardial
infarction has not been established.
Methods: A one hundred sixty-eight AMI patients compared to 169
healthy controls.
Results: No association between LPA C93T genotypes and AMI was
found. The frequencies of the GG, GA and AA genotypes of LPA G121A
polymorphism were not significantly different in AMI patients and in healthy
controls (45.2 %, 48.2%, 6.6 % vs 41.7 %, 49.4 %, 8.9%, P=0.880). In multi-
variate logistic regression analysis with covariates including traditional risk
factors (diabetes, hypertension, smoking and cholesterol) and, The C93T and
G121A polymorphisms, hypertension was independently associated with
increased risk of AMI (OR=3.5, P=0.044). 
Conclusion: The C93T and G121A polymorphisms of the LPA gene is not
associated with susceptibility to acute myocardial infarction
